12:00 AM
Jul 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Perifosine: Phase I started

Aeterna Zentaris said partner Yakult began an open-label, Japanese Phase I trial to evaluate 50 mg oral perifosine daily in 21-day cycles in combination with Velcade bortezomib and dexamethasone in about 18 patients with refractory MM who were treated with Velcade. In May, Aeterna and Keryx Biopharmaceuticals Inc. (NASDAQ:KERX,...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >